-
Je něco špatně v tomto záznamu ?
SARS-CoV-2 vaccination associated venous sinus thrombosis in three patients
J. Finsterer
Jazyk angličtina Země Česko
Typ dokumentu kazuistiky, časopisecké články
NLK
Directory of Open Access Journals
od 2019
ROAD: Directory of Open Access Scholarly Resources
od 2002
PubMed
36218128
DOI
10.32725/jab.2022.011
Knihovny.cz E-zdroje
- MeSH
- antikoagulancia škodlivé účinky MeSH
- COVID-19 * prevence a kontrola MeSH
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- messenger RNA MeSH
- pilotní projekty MeSH
- SARS-CoV-2 MeSH
- senioři nad 80 let MeSH
- trombóza nitrolebních žilních splavů * etiologie MeSH
- vakcinace škodlivé účinky MeSH
- vakcíny proti COVID-19 * škodlivé účinky MeSH
- virové vakcíny * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
INTRODUCTION: There is increasing evidence that vaccinations against the severe acquired respiratory syndrome coronavirus type-2 (SARS-CoV-2) virus can be followed by venous sinus thrombosis (VST). Here we report on three patients who developed VST shortly after SARS-CoV-2 vaccinations. CASE SERIES: An 80-year-old male, a 58-year-old male, and a 34-year-old female developed VST 14 to 24 days after the first dose of an mRNA-based SARS-CoV-2 vaccine. All three patients profited from analgesics, heparinisation, and oral anticoagulation, but made only an incomplete recovery at the time of discharge. Arguments for a causal relationship are: VST was time-linked to vaccination in the three patients; VST was previously reported after SARS-CoV-2 vaccination; SARS-CoV-2 infections can be complicated by VST; and SARS-CoV-2 can be associated with hypercoagulability. The fact that no hypercoagulability occurred in a pilot study after SARS-CoV-2 vaccination and that there has been no evidence of an increased prevalence/incidence of VST after vaccination since the introduction of the SARS-CoV-2 vaccination speak against a causal relationship. CONCLUSIONS: SARS-CoV-2 vaccinations can occasionally be followed by a VST. There are more arguments for than against a causal relationship.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22026979
- 003
- CZ-PrNML
- 005
- 20230210111624.0
- 007
- ta
- 008
- 221108s2022 xr a f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.32725/jab.2022.011 $2 doi
- 035 __
- $a (PubMed)36218128
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Finsterer, Josef $u Neurology & Neurophysiology Center, Vienna, Austria
- 245 10
- $a SARS-CoV-2 vaccination associated venous sinus thrombosis in three patients / $c J. Finsterer
- 520 9_
- $a INTRODUCTION: There is increasing evidence that vaccinations against the severe acquired respiratory syndrome coronavirus type-2 (SARS-CoV-2) virus can be followed by venous sinus thrombosis (VST). Here we report on three patients who developed VST shortly after SARS-CoV-2 vaccinations. CASE SERIES: An 80-year-old male, a 58-year-old male, and a 34-year-old female developed VST 14 to 24 days after the first dose of an mRNA-based SARS-CoV-2 vaccine. All three patients profited from analgesics, heparinisation, and oral anticoagulation, but made only an incomplete recovery at the time of discharge. Arguments for a causal relationship are: VST was time-linked to vaccination in the three patients; VST was previously reported after SARS-CoV-2 vaccination; SARS-CoV-2 infections can be complicated by VST; and SARS-CoV-2 can be associated with hypercoagulability. The fact that no hypercoagulability occurred in a pilot study after SARS-CoV-2 vaccination and that there has been no evidence of an increased prevalence/incidence of VST after vaccination since the introduction of the SARS-CoV-2 vaccination speak against a causal relationship. CONCLUSIONS: SARS-CoV-2 vaccinations can occasionally be followed by a VST. There are more arguments for than against a causal relationship.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a antikoagulancia $x škodlivé účinky $7 D000925
- 650 12
- $a COVID-19 $x prevence a kontrola $7 D000086382
- 650 12
- $a vakcíny proti COVID-19 $x škodlivé účinky $7 D000086663
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a pilotní projekty $7 D010865
- 650 _2
- $a messenger RNA $7 D012333
- 650 _2
- $a SARS-CoV-2 $7 D000086402
- 650 12
- $a trombóza nitrolebních žilních splavů $x etiologie $7 D012851
- 650 _2
- $a vakcinace $x škodlivé účinky $7 D014611
- 650 12
- $a virové vakcíny $7 D014765
- 655 _2
- $a kazuistiky $7 D002363
- 655 _2
- $a časopisecké články $7 D016428
- 773 0_
- $w MED00012667 $t Journal of applied biomedicine $x 1214-0287 $g Roč. 20, č. 3 (2022), s. 83-86
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36218128 $y Pubmed
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y p $z 0
- 990 __
- $a 20221108 $b ABA008
- 991 __
- $a 20230210111615 $b ABA008
- 999 __
- $a ok $b bmc $g 1896151 $s 1178286
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 20 $c 3 $d 83-86 $e 20220726 $i 1214-0287 $m Journal of Applied Biomedicine $n J. Appl. Biomed. (Čes. Budějovice Print) $x MED00012667
- LZP __
- $b NLK138 $a Pubmed-20221108